# Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania

> **NCT03602508** · — · COMPLETED · sponsor: **Astellas Pharma Singapore Pte. Ltd.** · enrollment: 5589 (actual)

## Conditions studied

- Overactive Bladder (OAB)

## Interventions

- **DRUG:** mirabegron
- **DRUG:** solifenacin
- **DRUG:** darifenacin
- **DRUG:** imidafenacin
- **DRUG:** tolterodine
- **DRUG:** oxybutynin
- **DRUG:** trospium
- **DRUG:** fesoterodine
- **DRUG:** propiverine

## Key facts

- **NCT ID:** NCT03602508
- **Lead sponsor:** Astellas Pharma Singapore Pte. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-20
- **Primary completion:** 2019-09-13
- **Final completion:** 2019-09-13
- **Target enrollment:** 5589 (ACTUAL)
- **Last updated:** 2024-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03602508

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03602508, "Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03602508. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*